Results 1 to 10 of about 125,839 (199)
Prasinezumab slows motor progression in Parkinsons disease: beyond the clinical data [PDF]
npj Parkinson's DiseaseA post hoc subgroup analysis has suggested potential therapeutic benefits of prasinezumab, a humanized monoclonal anti-α-synuclein antibody, in patients with rapidly progressing Parkinson’s disease (PD), despite initial trials showing limited impact on ...
Bin Xiao, Eng-King Tan
doaj +2 more sources
MedEdPORTAL, 2012 Parkinson's disease is a degenerative disorder of the central nervous system resulting from the death of dopamine producing cells in the substantia nigra.
Douglas Gould, Lisa Haubert
doaj +3 more sources
Therapeutic Implications and Regulations of Protein Post-translational Modifications in Parkinsons Disease. [PDF]
Cell Mol NeurobiolMishra T, Singh S, Singh TG.
europepmc +2 more sources
Mayo Clinic Proceedings, 2016 Parkinson disease (PD) is a progressive neurodegenerative disease that affects one million people in the United States. This article reviews the etiology and pathophysiology of PD, risk factors, clinical manifestations, diagnostic criteria, and treatment of this common disease. Implications for home care clinicians are included.
Rachael A, Vaubel +2 more
+7 more sources
Familial Parkinson’s Disease/Parkinsonism [PDF]
BioMed Research International, 2015 Parkinson's disease (PD) is the second most common neurodegenerative disorder characterized by parkinsonism (bradykinesia, resting tremor, rigidity, and postural instability) with good response to L-dopa. Although the majority of PD patients are sporadic, it is now clear that genetic factors contribute to the pathogenesis of PD.
Hiroyuki Tomiyama +3 more
openaire +2 more sources
Анналы клинической и экспериментальной неврологии, 2021 Levodopa (3-hydroxy-L-tyrosine, the levorotatory isomerof 3,4-dihydroxyphenylalanine) is a biological precursor of the neurotransmitter dopamine and has been the "gold standard" in the treatment of Parkinsons disease for over 50 years. The widespread use
Denis А. Abaimov +6 more
doaj +1 more source
The Lancet, 2021 Parkinson's disease is a recognisable clinical syndrome with a range of causes and clinical presentations. Parkinson's disease represents a fast-growing neurodegenerative condition; the rising prevalence worldwide resembles the many characteristics typically observed during a pandemic, except for an infectious cause.
Bloem, B.R., Okun, M.S., Klein, C.
openaire +2 more sources
Анналы клинической и экспериментальной неврологии, 2019 Parkinsons disease is an important medico-social problem worldwide, with a lot of attention paid to preclinical studies to assess the efficacy of new treatments, including cell therapy. Study objective.
Marina M. Zafranskaya +7 more
doaj +1 more source
Heterogeneity of sporadic Parkinson’s disease: molecular approach to solving the problem
Анналы клинической и экспериментальной неврологии, 2007 We performed search for mutations in the LRRK2, PRKN (parkin)and SNCA (a-synuclein) genes in 359 patients of Slavonic ethnicorigin (169 men and 190 women) with Parkinsons disease, ofwhom 345 represented sporadic cases. Age at the disease onset wasfrom 23
S. N. Illarioshkin +11 more
doaj +1 more source